Alaunos Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Alaunos Therapeutics generated cash of -$30,142,000, which is less than the previous year. Cash used in financing activities reached the amount of -$18,138,000 last year. Net change in cash is therefore -$46,934,000.
Cash Flow
| 2014 | -36.65M | -193K | 11.44M |
|---|---|---|---|
| 2015 | -10K | -412K | 98.33M |
| 2016 | -58.32M | -551K | -788K |
| 2017 | -54.66M | -737K | 45.29M |
| 2018 | -49.45M | -459K | 40.31M |
| 2019 | -40.85M | -284K | 59.15M |
| 2020 | -57.01M | -9.77M | 102.11M |
| 2021 | -61.46M | -3.32M | 25.77M |
| 2022 | -29.23M | -193K | 6.36M |
| 2023 | -30.14M | 1.34M | -18.13M |
TCRT Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 52.99M | 76.05M | 115.06M | 79.74M | 61.72M | 71.33M | 81.05M | 140.71M | 42.80M | 68.20M |
Operating activities | ||||||||||
Net income | -35.14M | -37.73M | -78.75M | -79.97M | -117.79M | -53.11M | -54.32M | -165.29M | -120.08M | -31.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.31M | 2.75M | 2.59M | 1.12M | 629K | 575K | 369K | 290K | 357K | 462K |
Stock-based compensation expense | 2.8M | 3.52M | 10.77M | 6.82M | 7.34M | 0 | 8.45M | 8.45M | 7.99M | 4.74M |
| Deferred income tax benefit | 2.8M | 3.52M | 10.77M | 6.82M | 7.34M | 0 | 8.45M | 8.45M | 7.99M | 4.74M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 3K | 1.10M | 3.55M | -1.33M | -1.46M | -1.84M | 2K | 425K | -301K | 0 |
Inventories | 0 | 0 | -3.55M | 1.33M | 1.46M | 1.53M | 0 | -12.24M | -8.49M | 0 |
Accounts payable | -773K | -25K | 274K | 54K | 199K | -3.70M | 4.26M | -1.85M | 4K | 1.58M |
Cash generated by operating activities | -30.14M | -29.23M | -61.46M | -57.01M | -40.85M | -49.45M | -54.66M | -58.32M | -10K | -36.65M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -197K | -216K | -3.32M | -9.77M | -284K | -459K | -737K | -551K | -412K | -193K |
Acquisitions Net | 0 | 23K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 1.34M | -193K | -3.32M | -9.77M | -284K | -459K | -737K | -551K | -412K | -193K |
Financing activities | ||||||||||
Common Stock Issued | 92K | 14.72M | 1.03M | 101.67M | 6.08M | 47.10M | 47.27M | 87K | 94.32M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -45K | 0 | 0 | -653K | -1.62M | -2.05M | -1.50M | -552K | -544K |
Repayments of term debt | -18.10M | -8.33M | -24.74M | 0 | 0 | -17.23M | 0 | -7.03M | 0 | 0 |
Cash used in financing activities | -18.13M | 6.36M | 25.77M | 102.11M | 59.15M | 40.31M | 45.29M | -788K | 98.33M | 11.44M |
Net Change In Cash | -46.93M | -23.05M | -39.01M | 35.32M | 18.01M | -9.60M | -10.10M | -59.66M | 97.91M | -25.40M |
Cash at end of period | 6.06M | 52.99M | 76.05M | 115.06M | 79.74M | 61.72M | 70.94M | 81.05M | 140.71M | 42.80M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |